The earnings call reflected positive momentum with strong revenue growth, particularly for IBSRELA and XPHOZAH, despite some challenges such as the net loss and the departure of the CFO. The company appears well-positioned for continued growth.

Company Guidance

During the Ardelyx second quarter 2025 earnings call, the company reported strong financial performance, highlighting $97.7 million in total revenue, marking a 33% year-over-year growth. IBSRELA generated $65 million in net sales, an 84% increase year-over-year and a 46% rise quarter-over-quarter, prompting Ardelyx to raise its full-year 2025 net sales revenue guidance for IBSRELA to between $250 million and $260 million. XPHOZAH also showed promising results with $25 million in net sales, reflecting a 7% sequential increase, or 27% when adjusted for a one-time reserve release in Q1. The company's gross to net deductions improved, with IBSRELA at approximately 32.2% and XPHOZAH at around 29%. Ardelyx reported an improved net loss of $19.1 million, compared to $41 million in the prior quarter, and strengthened its balance sheet by securing an additional $50 million in debt at an 8.7% interest rate. The company remains optimistic about its future growth, with a focus on maximizing shareholder value and achieving peak net sales opportunities totaling over $1.75 billion.

Strong Revenue Growth

Ardelyx reported $97.7 million in total revenue for Q2 2025, representing a 33% year-over-year growth.

IBSRELA Sales Surge

IBSRELA achieved net sales revenue of $65 million, marking an 84% year-over-year growth and a 46% quarter-over-quarter growth.

XPHOZAH Performance

XPHOZAH reported net sales revenue of $25 million in Q2 2025, a 27% increase compared to Q1, when adjusted for a one-time reserve.

Improved Financial Flexibility

The company enhanced its financial flexibility by drawing an additional $50 million of debt at a favorable interest rate.

Leadership Expansion

Ardelyx appointed several new executives to its leadership team, including a Chief Business Officer and Chief Patient Officer, to support growth.

Ardelyx (ARDX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ARDX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 30, 2025	2025 (Q3)	-0.06 / -	0	―	―	―
Aug 04, 2025	2025 (Q2)	-0.13 / -0.08	-0.07	-14.29% (>-0.01)	―
May 01, 2025	2025 (Q1)	-0.11 / -0.17	-0.11	-54.55% (-0.06)	―
Feb 20, 2025	2024 (Q4)	<0.01 / 0.02	-0.12	116.67% (+0.14)	―
Oct 31, 2024	2024 (Q3)	-0.05 / 0.00	0.03	―	―
Aug 01, 2024	2024 (Q2)	-0.11 / -0.07	-0.08	12.50% (<+0.01)	―
May 02, 2024	2024 (Q1)	-0.15 / -0.11	-0.13	15.38% (+0.02)	―
Feb 22, 2024	2023 (Q4)	-0.10 / -0.12	0.06	-300.00% (-0.18)	―
Oct 31, 2023	2023 (Q3)	-0.11 / 0.03	-0.14	121.43% (+0.17)	―
Aug 02, 2023	2023 (Q2)	-0.12 / -0.08	-0.19	57.89% (+0.11)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

ARDX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 04, 2025	$4.39	$5.13	+16.86%
May 01, 2025	$5.47	$4.13	-24.50%
Feb 20, 2025	$6.36	$5.72	-10.06%
Oct 31, 2024	$5.87	$6.09	+3.75%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.